Svitlana Tyekucheva

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.

Murali I, Kasar S, Naeem A, Tyekucheva S, Khalsa JK, Thrash EM, Itchaki G, Livitz D, Leshchiner I, Dong S, Fernandes SM, Getz G, Johnson A, Brown JR.

Blood. 2021 07 08. 138(1):44-56. PMID: 33684943

Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.

Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Heiden MGV, Fiorentino M, Ebot EM, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2021 Apr. 30(4):751-756. PMID: 33500320

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.

Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA.

Am J Hematol. 2021 04 01. 96(4):E95-E98. PMID: 33373063

Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.

Penney KL, Tyekucheva S, Rosenthal J, El Fandy H, Carelli R, Borgstein S, Zadra G, Fanelli GN, Stefanizzi L, Giunchi F, Pomerantz M, Peisch S, Coulson H, Lis R, Kibel AS, Fiorentino M, Umeton R, Loda M.

Mol Cancer Res. 2021 03. 19(3):475-484. PMID: 33168599

Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.

Stopsack KH, Huang Y, Tyekucheva S, Gerke TA, Bango C, Elfandy H, Bowden M, Penney KL, Roberts TM, Parmigiani G, Kantoff PW, Mucci LA, Loda M.

Clin Cancer Res. 2020 11 15. 26(22):5903-5913. PMID: 32913135

Systematic Assessment of Tumor Purity and Its Clinical Implications.

Haider S, Tyekucheva S, Prandi D, Fox NS, Ahn J, Xu AW, Pantazi A, Park PJ, Laird PW, Sander C, Wang W, Demichelis F, Loda M, Boutros PC.

JCO Precis Oncol. 2020. 4. PMID: 33015524

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.

Davids MS, Fisher DC, Tyekucheva S, McDonough M, Hanna J, Lee B, Francoeur K, Montegaard J, Odejide O, Armand P, Arnason J, Brown JR.

Leukemia. 2021 04. 35(4):1064-1072. PMID: 32820271

A New Classification of Benign, Premalignant, and Malignant Endometrial Tissues Using Machine Learning Applied to 1413 Candidate Variables.

Downing MJ, Papke DJ, Tyekucheva S, Mutter GL.

Int J Gynecol Pathol. 2020 Jul. 39(4):333-343. PMID: 31157686

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS.

Blood. 2019 Nov 13. 134(Supplement_1):32. PMID: 31723987

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR.

Lancet Haematol. 2019 Aug. 6(8):e419-e428. PMID: 31208944